Table 1 Baseline characteristics of the study population
Variable | Nevirapine n = 144 | Efavirenz n = 140 | P value |
|---|---|---|---|
Age, years: Mean ± SD | 36.7 ± 8.7 | 36.7 ± 7.6 | |
Gender, number (%) | |||
Male | 104 (72.2%) | 111 (79.3%) | |
Female | 40 (28.8%) | 29 (20.7%) | |
BMI, Kg/m2 Mean ± SD | 18.1 ± 3.3 | 18.5 ± 3.3 | |
CD4 count, cells/ul Median (Range) | 127 (9–569) | 133 (7–588) | 0.47 |
Viral load/ml Median (Range) | 334,225 (120–5,000,000) | 173,000 (230–5,800,000) | 0.17 |
WHO staging of HIV disease, number (%) | |||
Stage-1 | 4 (2.9%) | 3 (2.2%) | 0.03 |
Stage-3 | 39 (27.8%) | 21 (15.3%) | 0.04 |
Stage-4 | 97 (69.3%) | 113 (82.5%) | 0.04 |
Type of tuberculosis, number (%) | |||
PTB | 17 (16%) | 24 (20.7%) | 0.07 |
EPTB | 69 (65%) | 82 (70.7%) | |
Disseminated/Miliary TB | 20 (19%) | 10 (8.6%) | |
Category of ATT, number (%) | 0.52 | ||
Category I | 124 (86.8%) | 124 (89.2%) | |
Category II | 19 (13.3%) | 15 (10.8%) | |
ATT-ART gap, days: Median (Range) | 27 (−1 to 100) | 26 (4 to 96) | 0.33 |